ABSTRACT
No abstract available.
Subject(s)
Humans , Male , Middle Aged , Antineoplastic Agents/adverse effects , Bone Marrow Cells/metabolism , Karyotyping , Leukemia, Myeloid, Acute/chemically induced , Leukemia, Promyelocytic, Acute/drug therapy , Oncogene Proteins, Fusion/genetics , Remission Induction , Tretinoin/therapeutic useABSTRACT
No abstract available.
Subject(s)
Adult , Humans , Male , Antimetabolites, Antineoplastic/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bone Marrow Examination , Chemotherapy, Adjuvant , Colectomy , Colorectal Neoplasms/drug therapy , Cytogenetic Analysis , Fluorouracil/adverse effects , Leukemia, Myeloid, Acute/chemically induced , Treatment OutcomeABSTRACT
The inv(16)(p13q22) is found in de novo AML and is closely associated with the FAB subtype M4eo. The inv(16) is rarely reported in therapy-related AML (t-AML) patients. Herein, we report a case of t-AML with inv(16) after combination chemotherapy using antimitotic agent and alkylating agent (cis-platin-paclitaxel) for ovarian serous cystadenocarcinoma.
Subject(s)
Female , Humans , Middle Aged , Antimitotic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chromosomes, Human, Pair 16/genetics , Cisplatin/adverse effects , Chromosome Inversion , Leukemia, Myeloid, Acute/chemically induced , Taxoids/adverse effectsABSTRACT
A 10-year-old boy was admitted with complaints of fever, pallor, fatigue and skin bleeds of 10 days duration and diagnosed as very severe aplastic anemia. He was given intensive immunosuppressive therapy but showed no response to therapy. He later evolved into acute myeloid leukemia. The occurrence of AML is reviewed and possible pathogenesis is discussed.
Subject(s)
Anemia, Aplastic/diagnosis , Antilymphocyte Serum/adverse effects , Child , Cyclosporine/adverse effects , Humans , Immunosuppressive Agents/adverse effects , Leukemia, Myeloid, Acute/chemically induced , MaleABSTRACT
This is a case report of a ten year old girl with ovarian germ cell tumor who was successfully treated with BEP chemotherapy. She developed acute myloid leukemia, AML-M5 with t(11;19)(q23;p13), 29 months after being off therapy. She received a cumulative dose of 2000 mg/m2 of etoposide and 400 mg/m2 of cisplatin. The association of etoposide and therapy related leukemia is reviewed.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Child , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 19 , Cisplatin/administration & dosage , Etoposide/administration & dosage , Female , Germinoma/complications , Humans , Leukemia, Myeloid, Acute/chemically induced , Ovarian Neoplasms/complications , Translocation, GeneticABSTRACT
A leucose aguda näo linfoblásticas é uma das complicaçöes tardías do tratamento de tumores sólidos e hematopoiéticos. Desenvolve-se principalmente com o uso de poliquimioterapia intensiva. Metade dos casos pode apresentar sinais de envolvimento de múltiplas linhagens hematopoiéticas, sendo de difícil classificaçäo pelos métodos morfológicos convencionais. Uma proporçäo de pacientes apresenta fase inicial de mielodisplasia com citopenais, havendo sugestöes de que a fase leucêmica seja o evento final do processo neoplásico secundário. Anomalias dos cromosomos 5 e/ou 7 estäo associados a estas leucoses. A poliquimioterapia convencional pode obter remissäo em cerca de 40% dos pacientes e uma sobrevida de 12 meses em 25%. A relaçäo risco/benefício deve ser sempre cuidadosamente estudada ao se abordar esquemas antitumorais, devendo-se levar em conta a possibilidade de leucemogênese no tratamento bem sucedido